Avodart (dutasteride), a new drug for benign prostatic hyperplasia
December 2002
GlaxoSmithKline is now marketing Avodart (dutasteride), a new drug for benign prostatic hyperplasia.
It's being promoted as better than Proscar (finasteride) because it blocks the two types of 5-alpha reductase.
Proscar selectively blocks only type 2.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote